drugset / Trial / NCT03876925
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib,single arm,open label study evaluating the safety and efficacy of CT053PTSA in patients with advanced and metastatic renal cell cancer who have progressed from previous treatment
Timeline
- Start
- 2018-06-25
- Primary completion
- 2020-03-01
- Completion
- 2020-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT053PTSA | Unknown | 60 mg | Oral |
| Subject | CT053PTSA | Unknown | 100 mg | Oral |